

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

MARGISON ET AL

Serial No. 09/700,259

Group Art Unit: Unknown

Filed: November 14, 2000

Examiner: Unknown

For: GENE THERAPY VECTORS
AND THEIR USE IN ANTITUMOUR
THERAPY

October 30, 2001

PRELIMINARY AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Please amend the above application as follows:

IN THE CLAIMS

Cancel claims 51, 52 and 53.

Please enter the following amended claims:

3. (Amended) Vector material as claimed in Claim 2 wherein the tumour-sensitizing expression product is a prodrug activating enzyme selected from the group consisting of:

HSV thymidine kinase, nitroreductase, cytosine deaminase, cytochrome p450

2E1 and cytochrome p450 2DV1.